公开(公告)号：US20140005198A1

公开(公告)日：2014-01-02

申请号：US14012861

申请日：2013-08-28

Applicant: AMGEN INC.

Inventor： Adrian L. SMITH ,  Elizabeth M. DOHERTY ,  Qi HUANG ,  Gang LIU

IPC: C07D487/04 ,  C07D473/00

CPC classification number: C07D487/04 ,  C07D473/00

Abstract: The present invention comprises a new class of compounds capable of modulating the activity of Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, A5, A6, A7, A8, A9, bond B, X, rings Z1 and Z2, R1 and R3 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

Abstract translation: 本发明包括能够调节Raf激酶活性的新一类化合物，因此可用于治疗Raf激酶介导的疾病，包括黑素瘤，肿瘤和其它癌症相关病症。 该化合物具有通式I，其中A1，A2，A3，A4，A5，A6，A7，A8，A9，键B，X，环Z1和Z2，R1和R3各自定义。 本发明还包括药物组合物，用于治疗Raf激酶介导的疾病的方法，以及可用于制备本发明化合物的中间体和方法。